Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 18/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22103350 | 1.00 | MAT2A (0.49) | MAT2AHRH4RXFP1 | |
| SCHEMBL30894478 | 0.96 | MAT2A (0.47) | MAT2AHRH4 | |
| SCHEMBL22103554 | 0.96 | MAT2A (0.47) | MAT2AHRH4 | |
| SCHEMBL22093050 | 0.89 | MAT2A (0.51) | MAT2AHRH4RXFP1 | |
| SCHEMBL22094146 | 0.88 | MAT2A (0.50) | MAT2AHRH4 | |
| SCHEMBL29569921 | 0.88 | MAT2A (0.50) | MAT2AHRH4 | |
| SCHEMBL29570300 | 0.86 | MAT2A (0.48) | MAT2A | |
| SCHEMBL22093601 | 0.86 | MAT2A (0.48) | MAT2A | |
| SCHEMBL22103519 | 0.86 | MAT2A (0.53) | MAT2ARXFP1 | |
| SCHEMBL22093494 | 0.86 | MAT2A (0.48) | MAT2AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240269143-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | GLAXOSMITHKLINE LLC | 2024-08-15 | — | — | US | disclosed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | MAT2A 3/4885HRH4 3945/4885RXFP1 4113/4885 |
| US-20240269143-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | PRMT1, PRMT6, MNAT1 | MAT2A 7/4885HRH4 3754/4885RXFP1 3897/4885 |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | PRMT1, PRMT6, MAT2A | MAT2A 3/4885HRH4 3945/4885RXFP1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.